化学抗原受体设计的重大进展和演变
Anna Gaimari1, Anna De Lucia1, Fabio Nicolini1
1Scientific Institute for Research, Hospitalization and Healthcare, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 40121 Meldola, Italy.
International journal of molecular sciences
|November 27, 2024
概括
化学抗原受体 (CAR) T细胞疗法对癌症治疗有希望,但面临挑战. 在CAR设计方面的创新,包括通用和酶分泌CAR,旨在提高患者的安全性和有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 癌症免疫疗法取得了显著的进步,采用细胞疗法 (ACT) 和仿真抗原受体 (CAR) T 细胞疗法成为关键策略.
- 卡尔-T细胞是针对瘤抗原的工程T细胞,具有长期癌症缓解的潜力.
- 现有的CAR-T疗法面临抗原逃逸和细胞因子释放综合征等挑战,需要进一步优化.
研究的目的:
- 审查CAR-T细胞治疗中的挑战和创新策略.
- 突出CAR结构设计和各种治疗方法的进步.
- 引导研究人员在不断发展的ACT领域.
主要方法:
- 对当前CAR-T细胞治疗文献的系统综述.
- 基于结构和功能的CAR构造的分类.
- 讨论新的CAR设计,包括通用,双重,超级,酶分泌和刺激反应的CAR.
- 探索基因工程技术,如CRISPR/Cas9和TALENs,以改善CAR.
主要成果:
- 在CAR-T细胞疗法设计和应用方面取得了重大进展.
- 引入先进的汽车类型,如通用汽车,双重汽车和超级汽车.
- 开发具有增强功能的CAR,包括酶分泌 (catalase,heparanase) 和对外部刺激 (光,热,氧,纳米材料) 的反应能力.
- 整合基因组编辑技术,以改善CAR结构.
结论:
- 创新的CAR设计和治疗策略对于克服CAR-T细胞疗法的当前局限性至关重要.
- 先进的CAR结构和基因工程有望为更安全,更有效的癌症治疗提供希望.
- 对这些精细方法进行进一步的临床评估对于更广泛的患者应用至关重要.
更多相关视频
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
461
相关概念视频
01:28Diversity of Antigen Receptors
525
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
525
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K